跳至主要内容
临床试验/NCT01531621
NCT01531621招募中不适用

A Population-based Prospective Study to Evaluate Clinical Behaviour, Resectability and Survival in 1st Line Metastatic Colorectal Cancer (CRC) Patients in Finland

Pia Osterlund1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2012年2月最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000
试验地点
1
主要终点
Resectability

研究概览

简要总结

  • A population-based prospective study to evaluate clinical behaviour, resectability and survival in 1st line metastatic colorectal cancer (CRC) patients in Finland
  • Primary objective: To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection
  • Secondary objectives: To assess treatments for mCRC; To assess efficacy of chemotherapy and targeted drugs with overall response rates (ORR), failure free survival (FFS), progression free survival (PFS), and overall survival (OS); To radiologically assess tumour density and morphology, and assess alternative radiologic response evaluation in comparison with RECIST response criteria; To evaluate whole blood, plasma, serum and tumour block biomarkers and DNA polymorphisms that may predict drug effects, resectability and clinical behaviour of the tumour

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with histologically confirmed CRC, who are scheduled to start or are getting first line chemotherapy for metastatic disease
  • Metastatic disease (including locally advanced disease not amenable with surgery and/or (chemo)radiotherapy)
  • Signed written informed consent according to ICH/GCP and the local regulations (approved by the Independent Ethics Committee [IEC]) will be obtained prior to study
  • No informed consent will be obtained from patients participating in the data collection study obtaining data from hospital charts. No blood sampling, nor contacting of patients will be performed.

排除标准

  • 未提供

结局指标

主要结局

Resectability

时间窗: 5 years

To assess clinical behaviour of metastatic colorectal cancer and overall resectability, postoperative morbidity and outcomes after resection

次要结局

  • Efficacy(5 years)
  • Radiological assessment(5 years)
  • Safety(5 years)

研究者

发起方
Pia Osterlund
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Pia Osterlund

Principal Investigator

Helsinki University Central Hospital

研究点 (1)

Loading locations...

相似试验